- Infliximab (IFX),
- Adalimumab (ADL)
- Vedolizumab (VDL)
- Ustekinumab (UTK)
- Golimumab (GLM)
- Etanercept (ETN)
- Rituximab (RTX)
- Tocilizumab (TCZ)
Oncology Therapeutic Drug Monitoring Market size is valued at USD x million in 2021 and is expected to reach a value of USD x million by 2028, growing at a CAGR of x% during the forecast period 2022 to 2028. The global market provides a detailed overview of the Oncology Therapeutic Drug Monitoring Market and that can be segmented by monoclonal antibody type, and technology type. By monoclonal antibody type, the Oncology Therapeutic Drug Monitoring Market has been segmented into infliximab (IFX), adalimumab (ADL), vedolizumab (VDL), ustekinumab (UTK), golimumab (GLM), Etanercept (ETN), rituximab (RTX), tocilizumab (TCZ)). The golimumab (GLM)segment is likely to be the largest and fastest-growing segment in terms of monoclonal antibody type. Based on technology type, the Oncology Therapeutic Drug Monitoring Market is segmented into immunoassay and others. Among these, the immunoassay segment is expected to have the fastest-growing market during the forecast period 2022-2028.
Oncology Therapeutic Drug Monitoring Market Key Developments:
In July 2021, Roche announced the approval of "Ronapreve" (casirivimab and indevimab) for intravenous infusion treatment of patients with mild to moderate COVID-19. Under Article 14-3 of the Pharmaceuticals and Medical Devices Act, the antibody combination received Special Approval.
Oncology Therapeutic Drug Monitoring Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
X%
Largest Market
North America
Fastest Growing Market
North America
Oncology Therapeutic Drug Monitoring Market Dynamics
The market has been growing due to the rising demand for monoclonal antibodies (mABs) as a result of the COVID-19 pandemic. The Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for three monoclonal antibodies intended for outpatient treatment of symptomatic COVID-19 patients in response to the high transmission and significant fatality rates.
North-America Got Significant Share of
Oncology Therapeutic Drug Monitoring Market Regional Analysis
North American market is expected to witness the highest market share during the forecast period due to the well-established healthcare infrastructure. Furthermore, over the projected period, increased government support for cancer research and technology development is expected to stimulate the development of therapeutic proteins. Other major factors assisting the expansion of the industry are government assistance for infection control and management, the rising incidence of lifestyle-related disorders, and the growing population.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The oncology therapeutic drug monitoring market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Oncology Therapeutic Drug Monitoring Market Segmentation
By Monoclonal Antibody
By Technology
- Immunoassay
- Others
By Geography
- North America
- Europe,
- Asia Pacific
- Latin America
- Middle East and Africa
Frequently Asked Questions
The oncology therapeutic drug monitoring market size was valued at USD x billion in 2022
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The oncology therapeutic drug monitoring market key players are Grifols, S.A., Miraca Life Sciences, Prometheus Laboratories Inc., R-biopharm
| 1. Executive Summary |
| 2. Global Oncology Therapeutic Drug Monitoring Market Introduction |
| 2.1. Global Oncology Therapeutic Drug Monitoring Market Taxonomy |
| 2.2. Global Oncology Therapeutic Drug Monitoring Market Definitions |
| 2.2.1. Monoclonal Antibody Type |
| 2.2.2. Technology Type |
| 2.2.3. Region |
| 3. Global Oncology Therapeutic Drug Monitoring Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Oncology Therapeutic Drug Monitoring Market Dynamic Factors - Impact Analysis |
| 3.6. New Monoclonal Antibody Monitoring Test Launches |
| 3.7. Mergers and Acquisitions |
| 4. Global Oncology Therapeutic Drug Monitoring Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Oncology Therapeutic Drug Monitoring Market, By Monoclonal Antibody Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1. Infliximab (IFX) |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Adalimumab (ADL) |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Vedolizumab (VDL) |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Ustekinumab (UTK) |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Golimumab (GLM) |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Etanercept (ETN) |
| 5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Rituximab (RTX) |
| 5.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. Tocilizumab (TCZ) |
| 5.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 6. Global Oncology Therapeutic Drug Monitoring Market Forecast, By Technology, 2018 - 2022 and Forecast, 2023 - 2029 |
| 6.1. Immunoassay |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Others |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Global Oncology Therapeutic Drug Monitoring Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. EMEA (Europe, Middle East and Africa) |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Global Oncology Therapeutic Drug Monitoring Market - Opportunity Analysis Index, By Monoclonal Antibody Type, Technology Type, and Region, 2023 - 2029 |
| 8. North America Oncology Therapeutic Drug Monitoring Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1. Monoclonal Antibody Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Infliximab (IFX) |
| 8.1.2. Adalimumab (ADL) |
| 8.1.3. Vedolizumab (VDL) |
| 8.1.4. Ustekinumab (UTK) |
| 8.1.5. Golimumab (GLM) |
| 8.1.6. Etanercept (ETN) |
| 8.1.7. Rituximab (RTX) |
| 8.1.8. Tocilizumab (TCZ) |
| 8.2. Technology Analysis, 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Immunoassay |
| 8.2.2. Others |
| 8.3. Country Analysis 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. U.S. |
| 8.3.2. Canada |
| 8.4. North America Oncology Therapeutic Drug Monitoring Market - Opportunity Analysis Index, By Monoclonal Antibody Type, Technology, and Country, 2023 - 2029 |
| 8.5. North America Oncology Therapeutic Drug Monitoring Market Dynamics Trends |
| 9. EMEA Oncology Therapeutic Drug Monitoring Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.1. Monoclonal Antibody Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Infliximab (IFX) |
| 9.1.2. Adalimumab (ADL) |
| 9.1.3. Vedolizumab (VDL) |
| 9.1.4. Ustekinumab (UTK) |
| 9.1.5. Golimumab (GLM) |
| 9.1.6. Etanercept (ETN) |
| 9.1.7. Rituximab (RTX) |
| 9.1.8. Tocilizumab (TCZ) |
| 9.2. Technology Analysis, 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Immunoassay |
| 9.2.2. Others |
| 9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Germany |
| 9.3.2. UK |
| 9.3.3. Spain |
| 9.3.4. Italy |
| 9.3.5. France |
| 9.3.6. Saudi Arabia |
| 9.3.7. Rest of EMEA |
| 9.4. EMEA Oncology Therapeutic Drug Monitoring Market - Opportunity Analysis Index, By Monoclonal Antibody Type, Technology, and Country, 2023 - 2029 |
| 9.5. EMEA Oncology Therapeutic Drug Monitoring Market Dynamics Trends |
| 10. Asia-Pacific Oncology Therapeutic Drug Monitoring Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.1. Monoclonal Antibody Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Infliximab (IFX) |
| 10.1.2. Adalimumab (ADL) |
| 10.1.3. Vedolizumab (VDL) |
| 10.1.4. Ustekinumab (UTK) |
| 10.1.5. Golimumab (GLM) |
| 10.1.6. Etanercept (ETN) |
| 10.1.7. Rituximab (RTX) |
| 10.1.8. Tocilizumab (TCZ) |
| 10.2. Technology Analysis, 2017 - 2017 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Immunoassay |
| 10.2.2. Others |
| 10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Japan |
| 10.3.2. China |
| 10.3.3. India |
| 10.3.4. Rest of Asia-Pacific |
| 10.4. Asia-Pacific Oncology Therapeutic Drug Monitoring Market - Opportunity Analysis Index, By Monoclonal Antibody Type, Technology, and Country, 2023 - 2029 |
| 10.5. Asia-Pacific Oncology Therapeutic Drug Monitoring Market Dynamics Trends |
| 11. Latin America Oncology Therapeutic Drug Monitoring Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 11.1. Monoclonal Antibody Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Infliximab (IFX) |
| 11.1.2. Adalimumab (ADL) |
| 11.1.3. Vedolizumab (VDL) |
| 11.1.4. Ustekinumab (UTK) |
| 11.1.5. Golimumab (GLM) |
| 11.1.6. Etanercept (ETN) |
| 11.1.7. Rituximab (RTX) |
| 11.1.8. Tocilizumab (TCZ) |
| 11.2. Technology Analysis, 2017 - 2017 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Immunoassay |
| 11.2.2. Others |
| 11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Mexico |
| 11.3.3. Rest of Latin America |
| 11.4. Latin America Oncology Therapeutic Drug Monitoring Market - Opportunity Analysis Index, By Monoclonal Antibody Type, Technology, and Country, 2023 - 2029 |
| 11.5. Latin America Oncology Therapeutic Drug Monitoring Market Dynamics Trends |
| 12. Competition Landscape |
| 12.1. Strategic Dashboard of Top Market Players |
| 12.2. Company Profiles (Introduction, Financial Analysis, Monoclonal Antibody Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 12.2.1. Grifols, S.A. |
| 12.2.2. Miraca Life Sciences |
| 12.2.3. Prometheus Laboratories Inc. |
| 12.2.4. R-biopharm |
| 12.2.5. BÃœHLMANN |
| 13. Research Methodology |
| 14. Key Assumptions and Acronyms |
- Grifols, S.A.
- Miraca Life Sciences
- Prometheus Laboratories Inc.
- R-biopharm
- BÃœHLMANN